Hengrui's market capitalization broke 300 billion pharmaceutical companies ranked reshuffle

As of the close of trading on June 6, Hengrui Pharmaceuticals had broken the 300 billion mark, with a total market capitalization of 303.470 billion yuan, and just six months after Hengrui reached the 200 billion steps, it became a well-deserved "brother" of Chinese pharmaceutical stocks.
300 billion yuan in market capitalisation, valuations have risen to 90 times. However, performance did not see a corresponding improvement. On April 26, Hengrui Pharmaceuticals released its first-quarter 2018 report, which showed that its first-quarter operating income was RMB3,857 million and net profit was RMB949 million, up 21.70 percent and 16.95 percent respectively from the same period last year.
First quarter performance slowdown situation may soon change, 2018 Hengrui Pharma will usher in an intensive harvest period, since mid-to-late May, Hengrui Pharmaceutical research and development projects continue to be good news, a number of drugs have been clinical approval or new drug certificates.
New Kangjie statistics found that Hengrui Pharma recently obtained five "drug clinical trial approvals", 3 of which belong to the field of cancer treatment. Among them, the latest announcement for thiopei non-Gestin injection (19K) was approved for the market, the original research drug for Amgen company Neulasta, in 1991 approved by the FDA listed, becoming the world's first recombinant human granulocyte stimulation factor, global sales in 2017 reached $1.76 billion, but not listed in China. Hengrui Pharmaceuticals has invested 98 million yuan in the research and development project of sulfur-pei non-Gestin injection, which is expected to drive the company's performance growth after listing.
find that research and development capabilities are the key driving force driving the rise of Hengrui Pharmaceuticals shares. On May 30, Forbes magazine released its 2018 list of the world's top 100 most innovative companies, with seven companies in China, and Hengrui Pharmaceuticals, the only Chinese-owned pharmaceutical company, up 18 places from last year to 64th. In 2017, Hengrui Pharmaceuticals invested 1,759 million yuan in research and development, up 48.53 percent year-on-year, accounting for 12.71 percent of revenue, compared with multinational giants such as Johnson and Johnson.
It is worth mentioning that 18 large health sector companies, such as Hengrui Pharmaceuticals, were included in the MSCI Emerging Markets Index and successfully "entered the market", while boosting investor sentiment, the proportion of professional institutional investors will continue to rise as overseas investors' participation in A-shares increases further. In addition, the Shanghai Stock Exchange and the Shanghai Composite Index recently announced that from June 11, Hengrui Pharma and Qingdao Haier, 360 and other stocks adjusted to enter the Shanghai 50.Second Chair
On May 30, Pharmaceutical Mingkangde ended 16 board-breaking paths, becoming the fastest pharmaceutical stock to break the market value of 100 billion yuan, the share price from the issue price of 21.6 yuan / share doubled to more than 100 yuan, as of The close of June 6, at 124.06 yuan, the total market value reached 129.269 billion yuan, sitting on the domestic pharmaceutical stock market value of the second chair.
can say that Drug Mingkang is a case in point for successful privatization.
2000, Li Ge returned home to create the drug Mingkangde. In 2007, it took seven years for Pharmaceuticals to become the first Chinese company to land on the NYSE. In the second seven-year period, in 2015, Drug Mingkang announced the completion of privatization and de-listing from the NYSE, with a market capitalisation of just $3.3 billion, or less than 22 billion yuan.
de-listing, Drug Mingkangde split its business into three units: The company landed on the new three boards in 2015, Pharmaceutical Ming Bio was listed in Hong Kong in 2017 and Pharmaceutical Mingkangde returned to A-shares in 2018.
recent years, Drug Mingkangde has maintained steady and rapid growth, achieving operating income of 4.878 billion yuan, 6,048 million yuan and 7.720 billion yuan in 2015, 2016 and 2017, with a three-year compound annual growth rate of 25.85 percent. According to the prospecto, the operating income range for the first quarter of 2018 is expected to be between 2,050 and 2,255 million yuan, an increase of 15.94%-27.53% over the same period last year.
, however, the dynamic price-to-earnings ratio of Psython is 111 times, potentially risking a share price bubble compared with its earnings growth. Last year, After 18 ups and downs, Huada Gene was once among the hundreds of billions of clubs, but then entered a period of shock, by June 6, Huada Gene's market value has fallen into the 50 billion range, just half a year of market value. Whether Drug Mingkangde can get out of the unicorn's growth path in the capital market and sit in the second chair remains to be seen.Seth World
Behind the two hundred billion innovative enterprises, the other "players" of the 100 billion clubs have quietly evolved into the "Three Nations Kill" situation.
In the past month, Fosun Pharma's capital market (market value of 114.941 billion yuan) has been quite volatile, with frequent changes in its senior personnel, and at the end of March, at the same time as the annual report was released, Fosun Pharma announced that Guo Guangchang, Chairman of Fosun Pharma International Limited, was no longer serving as a non-executive director of Fosun Pharma and a member of the Strategic Committee of the Board of Directors. In addition, Fosun Pharma's non-executive director Kang Wei and Fosun Pharma's vice president, Yin Ying, are no longer in the company's position. Fosun Pharma achieved operating income of RMB5,719 million in the first quarter, up 47.38 percent year-on-year, and non-profit profit of RMB527 million, up 1.72 percent year-on-year, according to the first quarter of 2018.
Kangmei Pharmaceuticals (market value of 126.197 billion yuan) as the industry leader in the whole industrial chain of Chinese medicine, trade in Chinese herbal medicine, to the commercial circulation of Chinese medicine tablets, to Chinese medicine large health consumer goods, multi-line business in each link to form a moon. On the one hand, the rapid expansion of the beverage market, on the other hand, with the hospital to form a deep cooperative relationship to create "Internet plus medical services" O2O model. In 2017, Kangmei Pharmaceuticals achieved operating income of RMB26,477 million, up 22.34% YoY, outstriing the pharmaceutical industry by nearly 10 percentage points, net profit of RMB4.101 billion, up 22.77%, and basic earnings per share up 17.7% 54%; In the first quarter of this year, the Company continued to maintain a good upward momentum, achieving operating income of RMB9.135 billion, up 27.68 percent year-on-year, net income of RMB1.423 billion, up 33.28 percent year-on-year, and basic earnings per share up 32.72 percent year-on-year.
It can be said that Yunnan White Medicine (market value of 116.095 billion yuan) is a classic example of brand empowerment, in 2017, Yunnan White Medicine completed the reform of mixed ownership, in the company's institutional mechanism and business development, but also harvest a large amount of cash inflow. In 2017, Yunnan White Pharmaceuticals achieved operating income of RMB24,315 million, up 8.50% YoY, and net profit of RMB3.145 billion, up 7.71% YoY. (New Kangjie)